scholarly journals Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patientdata meta-analysis

2021 ◽  
pp. 096228022110463
Author(s):  
Yan Liu ◽  
Mireille E Schnitzer ◽  
Guanbo Wang ◽  
Edward Kennedy ◽  
Piret Viiklepp ◽  
...  

Effect modification occurs while the effect of the treatment is not homogeneous across the different strata of patient characteristics. When the effect of treatment may vary from individual to individual, precision medicine can be improved by identifying patient covariates to estimate the size and direction of the effect at the individual level. However, this task is statistically challenging and typically requires large amounts of data. Investigators may be interested in using the individual patient data from multiple studies to estimate these treatment effect models. Our data arise from a systematic review of observational studies contrasting different treatments for multidrug-resistant tuberculosis, where multiple antimicrobial agents are taken concurrently to cure the infection. We propose a marginal structural model for effect modification by different patient characteristics and co-medications in a meta-analysis of observational individual patient data. We develop, evaluate, and apply a targeted maximum likelihood estimator for the doubly robust estimation of the parameters of the proposed marginal structural model in this context. In particular, we allow for differential availability of treatments across studies, measured confounding within and across studies, and random effects by study.

PLoS Medicine ◽  
2018 ◽  
Vol 15 (7) ◽  
pp. e1002591 ◽  
Author(s):  
Elizabeth P. Harausz ◽  
Anthony J. Garcia-Prats ◽  
Stephanie Law ◽  
H. Simon Schaaf ◽  
Tamara Kredo ◽  
...  

Biometrics ◽  
2020 ◽  
Vol 76 (3) ◽  
pp. 1007-1016
Author(s):  
Guanbo Wang ◽  
Mireille E. Schnitzer ◽  
Dick Menzies ◽  
Piret Viiklepp ◽  
Timothy H. Holtz ◽  
...  

2016 ◽  
Vol 49 (1) ◽  
pp. 1600993 ◽  
Author(s):  
Greg J. Fox ◽  
Andrea Benedetti ◽  
Helen Cox ◽  
Won-Jung Koh ◽  
Piret Viiklepp ◽  
...  

The role of so-called “group 5” second-line drugs as a part of antibiotic therapy for multidrug-resistant tuberculosis (MDR-TB) is widely debated. We performed an individual patient data meta-analysis to evaluate the effectiveness of several group 5 drugs including amoxicillin/clavulanic acid, thioacetazone, the macrolide antibiotics, linezolid, clofazimine and terizidone for treatment of patients with MDR-TB.Detailed individual patient data were obtained from 31 published cohort studies of MDR-TB therapy. Pooled treatment outcomes for each group 5 drug were calculated using a random effects meta-analysis. Primary analyses compared treatment success to a combined outcome of failure, relapse or death.Among 9282 included patients, 2191 received at least one group 5 drug. We found no improvement in treatment success among patients taking clofazimine, amoxicillin/clavulanic acid or macrolide antibiotics, despite applying a number of statistical approaches to control confounding. Thioacetazone was associated with increased treatment success (OR 2.6, 95% CI 1.1–6.1) when matched controls were selected from studies in which the group 5 drugs were not used at all, although this result was heavily influenced by a single study.The development of more effective antibiotics to treat drug-resistant TB remains an urgent priority.


The Lancet ◽  
2018 ◽  
Vol 392 (10150) ◽  
pp. 821-834 ◽  
Author(s):  
Nafees Ahmad ◽  
Shama D Ahuja ◽  
Onno W Akkerman ◽  
Jan-Willem C Alffenaar ◽  
Laura F Anderson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document